Analysts were expecting BioMarin Pharmaceutical Inc. (BMRN)  to report earnings of $0.01 per share for last quarter, but BMRN beat expectations with actual earnings of $0.05---4 cents above the consensus estimate. BMRN also issued earnings guidance for next quarter that is in line with current analyst expectations.

If you compare last quarter's earnings to the $0.21 the company made per share during the same quarter a year ago, you can see that BMRN’s earnings are down this year.

By the way, did you know you could have made 191% on AAPL even though the stock only rose 28%. Learn how with this special report: 5 Profitable Options Trades for 2010

Also, if you compare BMRN's 24.33% projected earnings-per-share (EPS) growth rate for the next five years with the projected EPS growth rate of 15.43% for the Biotechnology industry as a whole during that same time frame, you can see that analysts expect BMRN to outperform the industry in the future---which is a good sign for the stock.

Help us out! Take this very short survey and tell us what kind of articles you'd like to see.

Drilling down a little deeper into the Biotechnology industry, you can see how analysts believe BMRN will stack up against some of the other stocks in the industry, like Genzyme Corp. (GENZ) and Gilead Sciences Inc. (GILD) , in the future. Analysts believe GENZ's earnings are going to grow at a rate of 20.15% while GILD's earnings are going to grow at a rate of 15.31%.

Earnings season can be a volatile time in the stock market. Check out these videos and articles to be better prepared to take advantage of the large price moves that tend to accompany earnings announcements.

Comments

Search RSS

All rights reserved."